Medpace (NASDAQ:MEDP) Shares Unloaded Rep. David Taylor

Representative David Taylor (R-Ohio) recently sold shares of Medpace Holdings, Inc. (NASDAQ:MEDP). In a filing disclosed on February 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Medpace stock on January 16th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Vertex Pharmaceuticals (NASDAQ:VRTX) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 1/29/2026.

Medpace Stock Down 3.3%

MEDP stock opened at $568.53 on Wednesday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The business has a 50-day simple moving average of $582.81 and a 200 day simple moving average of $536.08. The company has a market cap of $16.02 billion, a PE ratio of 39.76, a price-to-earnings-growth ratio of 1.98 and a beta of 1.42.

Analysts Set New Price Targets

MEDP has been the topic of a number of analyst reports. Barclays increased their price objective on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, TD Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Medpace currently has an average rating of “Reduce” and a consensus price target of $491.27.

Hedge Funds Weigh In On Medpace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its position in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Norges Bank bought a new position in shares of Medpace in the 2nd quarter valued at $66,597,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares in the last quarter. Clarkston Capital Partners LLC bought a new stake in Medpace during the 2nd quarter worth $40,569,000. Finally, Mawer Investment Management Ltd. grew its position in Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after acquiring an additional 121,213 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Activity

In other news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 320,192 shares of company stock valued at $192,909,762 over the last quarter. Corporate insiders own 20.30% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.